Octreotide Long Acting Release Injection

Get a Price/Quote

MOQ : 100 Packs

Octreotide Long Acting Release Injection Specification

Origin of Medicine
India

Life Span
24 months from manufacture date

Packaging Type
Vial and box with diluent

Salt Composition
Octreotide Acetate

Dosage Form
Long Acting Release (LAR) Injectable Suspension

Indication
Acromegaly, neuroendocrine tumors, carcinoid syndrome

Pacakaging (Quantity Per Box)
1 vial with diluent and injection kit

Brand Name
Octreotide LAR

Drug Type
Synthetic somatostatin analogue

Ingredients
Octreotide Acetate

Physical Form
Injection

Function
Inhibits excessive hormone secretion

Recommended For
Treatment of acromegaly, certain neuroendocrine tumors, and control of symptoms associated with carcinoid tumors

Dosage
As directed by the physician; commonly 10 mg, 20 mg, or 30 mg every 4 weeks via intramuscular injection

Dosage Guidelines
Administered by healthcare professionals only, according to prescribed schedule

Suitable For
Adults

Quantity
1 Vial

Storage Instructions
Store at 2C to 8C (Refrigerate, do not freeze). Protect from light.

Route of Administration
Intramuscular (IM) injection

Shelf Life After Reconstitution
Use immediately after reconstitution; discard any unused material

Color
White to off-white lyophilized powder

Prescription/Non-Prescription
Prescription

Side Effects
Possible side effects include gastrointestinal disturbances, gallstones, and injection site reactions

Patient Counseling Information
Injection to be given only by trained healthcare personnel

Contraindications
Hypersensitivity to octreotide or any component of the formulation

Reconstitution
Reconstitute with the provided diluent before use

Octreotide Long Acting Release Injection Trade Information

Minimum Order Quantity
100 Packs

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Packs Per Month

Delivery Time
10 Days

Main Domestic Market
All India

About Octreotide Long Acting Release Injection

Experience the phenomenal efficacy of Octreotide Long Acting Release (LAR) Injection, a venerable solution designed for dominant results in the treatment of acromegaly and neuroendocrine tumors. Presented as a white to off-white lyophilized powder, this prescription-only medication boasts a reduced dosing frequency - as little as one IM injection every four weeks. Reconstitute with the provided diluent, and administer by healthcare professionals for optimal safety and effect. Try now to secure a deal in clinically-proven symptom control and hormone regulation. Distributed from India, Octreotide LAR is your trusted ally in managing complex endocrine conditions.

Key Features and Site of Application

Octreotide Long Acting Release Injection is administered intramuscularly, ensuring targeted delivery to the muscle tissue. This controlled-release formulation is designed exclusively for adult use under professional supervision. Notable features include its synthetic somatostatin analogue action and easy reconstitution with the provided diluent. It comes as a single-use vial, ideal for healthcare settings. The product inhibits excessive hormone secretion and provides robust symptom management for acromegaly, certain neuroendocrine tumors, and carcinoid syndrome.

Supply Ability and Delivery Services

We guarantee steady supply ability, ensuring reliable availability of Octreotide LAR Injection for medical professionals and institutions. Benefit from flexible payment terms and swift delivery times, facilitated by trusted transport services for optimal storage conditions. Our goods transport process includes secure drop-off and careful handling to maintain product integrity from origin to destination. Rely on our efficient distribution channels across India to receive your injection kit safely and promptly.

FAQ's of Octreotide Long Acting Release Injection:

Q: How should Octreotide Long Acting Release Injection be prepared and administered?

A: Octreotide LAR Injection must be reconstituted with the provided diluent and administered intramuscularly by trained healthcare professionals immediately after preparation to ensure safety and efficacy.

Q: What are the benefits of using Octreotide LAR for patients with acromegaly or neuroendocrine tumors?

A: Octreotide LAR provides dominant symptom control and inhibits excessive hormone secretion, leading to improved management of acromegaly, neuroendocrine tumors, and carcinoid syndrome with a convenient reduced dosing schedule.

Q: When is Octreotide LAR Injection contraindicated?

A: This injection is contraindicated in patients with known hypersensitivity to octreotide or any component of the formulation. It must not be used by those with such allergies.

Q: Where can I purchase Octreotide LAR Injection and how is it supplied?

A: Octreotide LAR is available through licensed medical suppliers and traders in India, provided in a vial with diluent and injection kit, distributed by prescription only.

Q: What are the possible side effects associated with Octreotide LAR?

A: Possible side effects include gastrointestinal disturbances, gallstones, and injection site reactions. Discuss any concerns with your healthcare provider before starting treatment.

Tell us about your requirement